Merck & Co.: upcoming dates

Upcoming dates: 1 · All pins: 6

Next: MK-8527's Phase 3 Trial in Human Immunodeficiency Virus Reads Out, October 18, 2027.

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.

All Merck & Co. pins in search Wikipedia Website

Upcoming

Health09/20/2026@HealthDesk
MK-8527's Phase 3 Trial in Human Immunodeficiency Virus Reads Out
Merck & Co.Rahway, United States
Starts 10/18/2027ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins50% CONFIDENCEOverall confidence: 50%How well the pin's source and references back up its dates.Weighted average of how firmly 1 reference, the source included, supports the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 1.0 yearsClinicalTrials.gov^[1] lists 2027-10-18 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Merck & Co.'s phase 3 trial of MK-8527 in human immunodeficiency virus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,580 participants. Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.

Recent

Related tags

Merck & Co.: upcoming dates · Chronopin

Business10/04/2026@EconDesk
Merck Q2 2026: US$16.6 Billion Sales, Hikes Revenue Outlook, Terns Charge Hits Profit
126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.
Starts 08/04/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better62 days agoMerck's^[1][3] release is dated August 4, 2026 (6:30 am EDT) and CNBC's^[2] coverage is 'Published Tue, Aug 4 2026'.
On 4 August 2026 Merck reported second-quarter sales of US$16.6 billion, up 5 percent, with Keytruda at US$8.4 billion, and raised its 2026 sales outlook while a US$2.31 per share Terns charge caused a loss.
Health10/04/2026@HealthDesk
FDA Approves Merck's Lipfendra, the First Oral PCSK9 Inhibitor
126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.
Starts 07/16/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better81 days agoMerck's^[1][2] news release is dated July 16, 2026 and says the FDA 'has approved LIPFENDRA (enlicitide) tablets 20 mg'; Practical Neurology^[4] and the Family Heart^[5] Foundation report the same.
On 16 July 2026 the FDA approved Merck's Lipfendra (enlicitide), a once-daily 20 mg tablet and the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia.
Business10/04/2026@EconDesk
Merck to Buy Terns for US$6.7 Billion for a Leukemia Drug
126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.
Starts 03/25/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better194 days agoThe Merck and Terns news release (SEC^[1] Exhibit 99.1) is datelined 'RAHWAY, N.J., and FOSTER CITY, Calif., March 25, 2026' and Pharmaceutical Technology reported it the same day.
On 25 March 2026 Merck agreed to acquire Terns Pharmaceuticals for US$53.00 per share in cash, about US$6.7 billion, to get TERN-701, an oral allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia.
$6.7B
Business10/04/2026@EconDesk
Merck Completes Cidara Takeover to Add a Long-Acting Flu Antiviral
126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.
Starts 01/07/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better271 days agoMerck's^[1][3] release, dated January 7, 2026, says it 'today announced the successful completion of the cash tender offer' for Cidara, with the tender expiring 11:59 p.m. ET on January 6.
On 7 January 2026 Merck announced the completion of its cash tender offer for Cidara Therapeutics at US$221.50 per share, gaining CD388, a long-acting antiviral for preventing influenza.
Health10/04/2026@HealthDesk
FDA Approves Merck's Keytruda, the First Anti-PD-1 Cancer Drug in the US
126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.
Starts 09/04/2014CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better12.1 years agoMerck's^[1] release is dated September 4, 2014 and says the FDA 'has approved KEYTRUDA'; The Pharmaletter^[3] (5 September 2014) reports the agency announced it 'late yesterday'.
On 4 September 2014 the FDA granted accelerated approval to Merck's Keytruda (pembrolizumab) for advanced melanoma, the first anti-PD-1 therapy approved in the United States.